These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
330 related articles for article (PubMed ID: 18992652)
1. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. García Rodríguez LA; Tacconelli S; Patrignani P J Am Coll Cardiol; 2008 Nov; 52(20):1628-36. PubMed ID: 18992652 [TBL] [Abstract][Full Text] [Related]
2. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336 [TBL] [Abstract][Full Text] [Related]
3. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Johnsen SP; Larsson H; Tarone RE; McLaughlin JK; Nørgård B; Friis S; Sørensen HT Arch Intern Med; 2005 May; 165(9):978-84. PubMed ID: 15883235 [TBL] [Abstract][Full Text] [Related]
4. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. García Rodríguez LA; Varas-Lorenzo C; Maguire A; González-Pérez A Circulation; 2004 Jun; 109(24):3000-6. PubMed ID: 15197149 [TBL] [Abstract][Full Text] [Related]
5. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Andersohn F; Suissa S; Garbe E Circulation; 2006 Apr; 113(16):1950-7. PubMed ID: 16618816 [TBL] [Abstract][Full Text] [Related]
6. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Helin-Salmivaara A; Virtanen A; Vesalainen R; Grönroos JM; Klaukka T; Idänpään-Heikkilä JE; Huupponen R Eur Heart J; 2006 Jul; 27(14):1657-63. PubMed ID: 16731535 [TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Abraham NS; El-Serag HB; Hartman C; Richardson P; Deswal A Aliment Pharmacol Ther; 2007 Apr; 25(8):913-24. PubMed ID: 17402995 [TBL] [Abstract][Full Text] [Related]
8. Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. García Rodríguez LA; González-Pérez A BMC Med; 2005 Nov; 3():17. PubMed ID: 16316472 [TBL] [Abstract][Full Text] [Related]
9. Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction? van Staa TP; Rietbrock S; Setakis E; Leufkens HG J Intern Med; 2008 Nov; 264(5):481-92. PubMed ID: 18624902 [TBL] [Abstract][Full Text] [Related]
11. Cardiovascular complications of non-steroidal anti-inflammatory drugs. Fosslien E Ann Clin Lab Sci; 2005; 35(4):347-85. PubMed ID: 16254252 [TBL] [Abstract][Full Text] [Related]
12. Use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs in high doses increases mortality and risk of reinfarction in patients with prior myocardial infarction. Sørensen R; Abildstrom SZ; Torp-Pedersen C; Gislason GH J Cardiovasc Nurs; 2008; 23(1):14-9. PubMed ID: 18158501 [TBL] [Abstract][Full Text] [Related]
13. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Schjerning Olsen AM; Fosbøl EL; Lindhardsen J; Folke F; Charlot M; Selmer C; Lamberts M; Bjerring Olesen J; Køber L; Hansen PR; Torp-Pedersen C; Gislason GH Circulation; 2011 May; 123(20):2226-35. PubMed ID: 21555710 [TBL] [Abstract][Full Text] [Related]
14. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Lanas A; García-Rodríguez LA; Arroyo MT; Bujanda L; Gomollón F; Forné M; Aleman S; Nicolas D; Feu F; González-Pérez A; Borda A; Castro M; Poveda MJ; Arenas J; Am J Gastroenterol; 2007 Mar; 102(3):507-15. PubMed ID: 17338735 [TBL] [Abstract][Full Text] [Related]
15. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs. van der Linden MW; van der Bij S; Welsing P; Kuipers EJ; Herings RM Ann Rheum Dis; 2009 May; 68(5):668-73. PubMed ID: 18495734 [TBL] [Abstract][Full Text] [Related]
16. The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada. Varas-Lorenzo C; Castellsague J; Stang MR; Perez-Gutthann S; Aguado J; Rodriguez LA Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1016-25. PubMed ID: 19718696 [TBL] [Abstract][Full Text] [Related]